Germany’s Stada Arzneimittel AG has been on a rapid growth trajectory in the last couple of years, after being acquired by private-equity firms Bain Capital and Cinven in 2017.
In February this year, the firm announced a deal for 15 consumer healthcare brands from GlaxoSmithKline PLC – mainly in the cold & flu, pain and skin-care categories – adding to a basket of mainly UK-based skincare products it bought from GSK in June 2018. (Also see "Stada Grabs GSK Brands In Key EU Markets" - HBW Insight, 25 February, 2020
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?